GENINCODE PLC (GENI) — Interim results presentation

Investor webinar replay

Replay transcript excerpt

Good afternoon, and welcome to the GENINCODE PLC Interim Results Investor Presentation. Screen. Simply type in your questions and press send. Company may not be in a position to answer every question received during the meeting itself. However, the company can review all questions submitted today and publish responses, which is appropriate to do so. Before we begin, I would like to submit the following poll. And I would now like to hand you over to CEO, Matthew Walls. Good afternoon to you. Good afternoon, Alex, and, good afternoon, everyone. Welcome to the, interim results business update for GENINCODE. I'm here with Paul Fulgier, CFO at the Cavendish broker offices in London, Central London for those of you who know roughly where we are. We've got quite a bit to get through, so I'm gonna move at some pace through the presentation. We'll start with a brief introduction then move through the results, take a look at The US strategy, EU and UK, a little bit of an update on ROCA and then finish on the financials. I think again just to breeze through who we are as a company, we're a genetic testing company specializing in the area of polygenic risk assessment in and around cardiovascular disease. So this is for the prediction and prevention of cardiovascular disease using genetics. We're revenue generating and as perhaps most of you are aware that's starting to move quickly now. Test products are regulatory approved. We have an established business, which was started back in 2007 with Ferro Pharmaceuticals. And then in 2018, we spun out those two businesses to form GENINCODE. Globally leading evidence based, so significant. And over the last twelve months, we put a lot of new publications and advances around polygenics into the field. We'll touch on that as well. IP prot...